When HCV Next launched, the FDA had approved just one protease inhibitor. NS5A inhibitors were waiting in the wings for their chance to shine. But everyone was ready.
“The concern is not the pace of the FDA-approval process. The concern is that patients are dying of cirrhosis and liver cancer. We now have the tools to stop this disease and end pain and suffering,” Andrew J. Muir, MD, said in our very first cover story. “We can feel better that a number of combinations are moving toward approval. We are heading toward a place where there will be different regimens, which means more options. That’s a good thing.”
Click on our Retrospective below to see how our coverage and the field of HCV has changed over time.